 Anavex 2-73blarcamesine at high concentrations in early Alzheimers disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheons ALZ-801 reduces cognitive decline in ApoE4 carriers by about the same amount as Eisai and Biogens Leqembi and Aduhelm, but without the risks of brain bleeds and swelling. 